Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels

References

• Abernethy DR, Schwartz JB. (1999). Calcium-antagonist drugs. N Engl J Med 341:1447–57.
   PubMed Web of Science ®Google Scholar
• Balakumaran A, Campbell GA, Moslen MT. (1996). Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol 139:122–7.
   Google Scholar
• Bassett AL, Chakko S, Epstein M. (1997). Are calcium antagonists proarrhythmic? J Hypertens 15:915–23.
   Google Scholar
• Cranefield PF, Aronson RS, Wit AL. (1974). Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circ Res 34:204–13.
   Google Scholar
• Eisen MB, Spellman PT, Brown PO, Botstein D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863–8.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Levi AJ, Jones JV. (1995). Wall stress induced arrhythmia is enhanced by low potassium and early left ventricular hypertrophy in the working rat heart. Cardiovasc Res 29:555–62.
   Google Scholar
• Evans SJ, Levi AJ, Jones JV. (1996). Low magnesium enhances the pro-arrhythmic effect of low potassium in the hypertrophied rat heart but not in the normal rat heart. J Hypertens 14:635–44.
   Google Scholar
• Freir DB, Costello DA, Herron CE. (2003). A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol 89:3061–9.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Kadakia S, Cooper RS, Liao YL. (1991). Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 17:1277–82.
   PubMed Web of Science ®Google Scholar
• Ismail NA, Shaheen AA, el Sawalhi MM, Megahed YM. (1995). Effect of calcium channel antagonists in modifying the inhibitory influence of adenosine on insulin secretion. Arzneimittelforschung/Drug Res 45:865–8.
   Google Scholar
• Kannel WB, Abbott RD, Savage DD, McNamara PM. (1982). Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306:1018–22.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. (1972). Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 287:781–7.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. (1975). Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 51:606–13.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Gordon T, Castelli WP, Margolis JR. (1970). Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 72:813–22.
   PubMedGoogle Scholar
• McLenachan JM, Dargie HJ. (1990). Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 3:735–40.
   PubMed Web of Science ®Google Scholar
• McNamara RL, Tamariz LJ, Segal JB, Bass EB. (2003). Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139:1018–33.
   PubMed Web of Science ®Google Scholar
• McTavish D, Sorkin EM. (1989). Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19–76.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Hansen JF, Gibson RS, Schechtman KB, Boden WE. (2001). Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 19: 977–82.
   Google Scholar
• Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. (1984). Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 77:18–22.
   PubMed Web of Science ®Google Scholar
• Michels KB, Rosner BA, Manson JE, Stampfer MJ, Walker AM, Willett WC, Hennekens CH. (1998). Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses’ Health Study. Circulation 97:1540–8.
   PubMed Web of Science ®Google Scholar
• Novo S, Barbagallo M, Abrignani MG, Nardi E, Di Maria GU, Longo B, Mistretta A, Strano A. (1997). Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens 10:843–51.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW. (1995). The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 274:620–5.
   PubMed Web of Science ®Google Scholar
• Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32–45.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Messerli FH. (1992). Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 123:89–95.
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Herre JM, Lewis RM. (1985). The electrophysiologic effects of nisoldipine in the conscious dog. Am Heart J 109:529–32.
   Google Scholar
• Siegel D, Cheitlin MD, Black DM, Seeley D, Hearst N, Hulley SB. (1990). Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol 65:742–7.
   Google Scholar
• Singh BN, Hecht HS, Nademanee K, Chew CY. (1982). Electrophysiologic and hemodynamic effects of slow channel blocking drugs. Prog Cardiovasc Dis 25:103–32.
   Google Scholar
• Thum T, Borlak J. (2000). Gene expression in distinct regions of the heart. Lancet 355:979–83.
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. (2002). Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537–49.
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health (NIH). (1996). Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, National Academy Press, Washington, D.C., USA.
   Google Scholar
• Walles M, Mullett WM, Levsen K, Borlak J, Wunsch G, Pawliszyn J. (2002). Verapamil drug metabolism studies by automated in-tube solid phase microextraction. J Pharm Biomed Anal 30:307–19.
   PubMed Web of Science ®Google Scholar
• Zwadlo C, Borlak J. (2005). Disease-associated changes in the expression of ion channels, ion receptors, ion exchangers and Ca(2+)-handling proteins in heart hypertrophy. Toxicol Appl Pharmacol 207:244–56.
   Google Scholar